Evidence map›Paper›PMID 33440772›Full record

SynthesisBiomolecules2021

Efficacy and Safety of Mesenchymal Stem/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review.

Jeffrey Zheng-Hsien Ko, Sheeva Johnson, Maneesh Dave

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations.Clinical and experimental gastroenterology · 2024
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jeffrey Zheng-Hsien KoDepartment of Internal Medicine, Division of Gastroenterology and Hepatology, UC Davis Medical Center, UC Davis School of Medicine, 4150 V Street, Suite 3500, Sacramento, CA 95817, USA.
Sheeva JohnsonDepartment of Internal Medicine, Division of Gastroenterology and Hepatology, UC Davis Medical Center, UC Davis School of Medicine, 4150 V Street, Suite 3500, Sacramento, CA 95817, USA.
Maneesh DaveDepartment of Internal Medicine, Division of Gastroenterology and Hepatology, UC Davis Medical Center, UC Davis School of Medicine, 4150 V Street, Suite 3500, Sacramento, CA 95817, USA.
University of California Davis Medical Center · USCalifornia Institute for Regenerative Medicine · US

Funding

Novel immunosuppressive mechanism of human bone marrow mesenchymal stem cells in experimental Crohn’s diseaseK08DK110421 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAVE, MANEESH · 2017 to 2023
$980k
NIDDK NIH HHS K08 DK110421
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gut that can lead to severe gastrointestinal symptoms, malnutrition, and complications such as fistulas and cancer. Mesenchymal stem/stromal cells (MSCs) are being investigated as a novel therapy for IBD and have been demonstrated to be safe and effective for perianal fistulizing Crohn's disease (PFCD). This systematic review aims to present the most recent studies on the safety and efficacy of MSC therapy in IBD. A detailed search strategy of clinical trials on MSCs and IBD was performed on PubMed, with 32 studies selected for inclusion in this review. The newest studies on local MSC injection for PFCD continue to support long-term efficacy while maintaining a favorable safety profile. The evidence for systemic MSC infusion in luminal IBD remains mixed due to marked methodological heterogeneity and unclear safety profiles. Although further studies are needed to better establish the role of this novel treatment modality, MSCs are proving to be a very exciting addition to the limited therapies available for IBD.

Indexed as

Crohn DiseaseHumansInflammatory Bowel DiseasesInjectionsMesenchymal Stem CellsMesenchymal Stem Cell TransplantationCrohn’s diseaseefficacyinflammatory bowel diseasemesenchymal stem/stromal cellsperianal fistulasafetyulcerative colitis

Identifiers

PMID33440772
PMCPMC7827559
OpenAlexW3120301604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.